Teodoro Segura, MD
Allergy & Immunology · Omaha, NENPI 1578644035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,314 and has fallen 63.0% since, to $856 in 2024.
Across 479 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- GSK$979
- AstraZeneca$835
- Grifols USA, LLC$771
- Takeda Pharmaceuticals U.S.A., Inc.$572
- AbbVie$482
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,950100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 56 | $1,066 |
| GSK | 98 | $979 |
| AstraZeneca | 29 | $835 |
| Grifols USA, LLC | 42 | $771 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $572 |
| AbbVie | 28 | $482 |
| Regeneron Healthcare Solutions, Inc. | 23 | $475 |
| CSL Behring | 27 | $387 |
| Genentech USA, Inc. | 25 | $343 |
| Biocryst US Sales Co., LLC | 11 | $270 |
| Pfizer | 17 | $244 |
| Amgen(2 entities) | 9 | $198 |
| Pharming Healthcare, Inc. | 11 | $163 |
| Novartis | 8 | $133 |
| Alk-abello, Inc | 7 | $119 |
| Incyte Corporation | 7 | $118 |
| Bio Products Laboratory USA, Inc. | 9 | $114 |
| Octapharma USA, Inc. | 4 | $109 |
| Shire North American Group Inc | 7 | $93 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Optinose US, Inc. | 5 | $78 |
| Covis Pharma GmbH | 4 | $62 |
| Kaleo, Inc. | 4 | $58 |
| Blueprint Medicines Corporation | 2 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| LEO Pharma Inc. | 2 | $33 |
| Seqirus USA Inc | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,963 in reported general payments places this provider in the 55th percentile of 21 allergy & immunology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $49,857 |
| Dupixent PenDupilumab | 13 | $44,735 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $26,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $25,317 |
| Spiriva RespimatTiotropium Bromide | 21 | $10,403 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,599 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,847 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $2,937 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,748 |
| Azelastine Hcl | 63 | $1,656 |
| Fluticasone Propionate | 35 | $1,203 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $643 |
| Montelukast Sodium | 91 | $385 |
| Selenium Sulfide | 13 | $164 |
| Prednisone | 29 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $979 | $58,08185 claims |
| Boehringer IngelheimSpiriva Respimat | $14 | $10,40321 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $81 | $2,74811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 21 allergy & immunology providers in Nebraska.
Other allergy & immunology in Omaha
- James TracyOmaha$104K
- Roger KobayashiOmaha$45K
- Mitchell PitlickOmaha$26K
- James FriedlanderOmaha$22K
- Brett KettelhutOmaha$21K
- Gary KoenigOmaha$4K
- Sara MayOmaha$2K
- Brian KellyOmaha$1K
- Jose Zamora SifuentesOmaha$786
- Joel van de GraaffOmaha$692
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.